Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 "Biologic" level structures through chemistry: A total synthesis of a unimolecular pentavalent MUCI glycopeptide construct.

Literature DB >> 21423786

"Biologic" level structures through chemistry: A total synthesis of a unimolecular pentavalent MUCI glycopeptide construct.

Abstract

A convergent synthesis of a unimolecular pentavalent-MUC1 glycopeptide has been accomplished. A tandem repeat of unglycosylated human tumor-associated MUC1, a potential target for cancer immunotherapy, was incorporated into the known unimolecular pentavalent carbohydrate construct (5). This is an important step towards the development of a new fully synthetic anti-cancer vaccine candidate (1).

Entities: Chemical Disease Gene Species

Year: 2009 PMID： 21423786 PMCID： PMC3059311 DOI： 10.1016/j.tetlet.2009.02.138

Source DB: PubMed Journal: Tetrahedron Lett ISSN： 0040-4039 Impact factor: 2.415

28 in total

1. Organic synthesis in pursuit of immunology: large-scale synthesis of peracetylated GM2 glycosylamino acid for preparation of a multiantigenic prostate cancer vaccine.

Authors: Young Shin Cho; Qian Wan; Samuel J Danishefsky
Journal: Bioorg Med Chem Date: 2005-09-01 Impact factor: 3.641

Review 2. Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism.

Authors: S Hakomori
Journal: Cancer Res Date: 1996-12-01 Impact factor: 12.701

3. Specificity of glycopeptide-specific T cells.

Authors: B Deck; M Elofsson; J Kihlberg; E R Unanue
Journal: J Immunol Date: 1995-08-01 Impact factor: 5.422

Review 4. Synthetic carbohydrate-based antitumor vaccines: challenges and opportunities.

Authors: Ouathek Ouerfelli; J David Warren; Rebecca M Wilson; Samuel J Danishefsky
Journal: Expert Rev Vaccines Date: 2005-10 Impact factor: 5.217

5. Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group-related antigens.

Authors: S Zhang; H S Zhang; C Cordon-Cardo; V E Reuter; A K Singhal; K O Lloyd; P O Livingston
Journal: Int J Cancer Date: 1997-09-26 Impact factor: 7.396

6. CD1-restricted T cell recognition of microbial lipoglycan antigens.

Authors: P A Sieling; D Chatterjee; S A Porcelli; T I Prigozy; R J Mazzaccaro; T Soriano; B R Bloom; M B Brenner; M Kronenberg; P J Brennan
Journal: Science Date: 1995-07-14 Impact factor: 47.728

7. Mucin-like carcinoma-associated antigen serum levels in patients with adenocarcinomas originating from ovary, breast and colon.

Authors: G G Bon; R H Verheijen; J M Zuetenhorst; G J van Kamp; A A Verstraeten; P Kenemans
Journal: Gynecol Obstet Invest Date: 1996 Impact factor: 2.031

8. MUC1 mucin expression as a marker of progression and metastasis of human colorectal carcinoma.

Authors: S Nakamori; D M Ota; K R Cleary; K Shirotani; T Irimura
Journal: Gastroenterology Date: 1994-02 Impact factor: 22.682

9. Relationship between CA 15-3 serum levels and disease extent in predicting overall survival of breast cancer patients with newly diagnosed metastatic disease.

Authors: M Tampellini; A Berruti; A Gerbino; T Buniva; M Torta; G Gorzegno; R Faggiuolo; R Cannone; A Farris; M Destefanis; G Moro; F Deltetto; L Dogliotti
Journal: Br J Cancer Date: 1997 Impact factor: 7.640

10. Recognition of carbohydrate by major histocompatibility complex class I-restricted, glycopeptide-specific cytotoxic T lymphocytes.

Authors: J S Haurum; G Arsequell; A C Lellouch; S Y Wong; R A Dwek; A J McMichael; T Elliott
Journal: J Exp Med Date: 1994-08-01 Impact factor: 14.307

4 in total